APP
ENTA icon

Avantax Planning Partners’s Enanta Pharmaceuticals ENTA Stock Holding History

Avantax Planning Partners’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-500
Closed -$43K – 537
2018
Q3 		$43K Buy
+500
New +$50.1K ﹤0.01% 521
2018
Q2 		– Sell
-52
Closed -$4K – 578
2018
Q1 		$4K Buy
+52
New +$4K ﹤0.01% 1406

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Avantax Planning Partners's ENTA Position: Q4 2018 in Review

Avantax Planning Partners sold out of Enanta Pharmaceuticals (ENTA) in Q4 2018, closing a stake of 500 shares — an estimated $43K sold.

Avantax Planning Partners first reported a position in ENTA in Q1 2018 and held it in 2 quarters. The position peaked at $43K in Q3 2018. 183 funds tracked by Wall St. Rank hold ENTA as of Q4 2018.

  • Avantax Planning Partners reported no remaining Enanta Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 500 Enanta Pharmaceuticals shares in Q4 2018, an estimated $43K.
  • Avantax Planning Partners first reported a position in Enanta Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Avantax Planning Partners's Enanta Pharmaceuticals position peaked at $43K in Q3 2018.
  • 183 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2018.

Based on Avantax Planning Partners's 13F filing for Q4 2018, filed 14 Feb 2019.